Drug Trial Radar · NCT07018492
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Aug 30, 2025
Primary completion
Nov 26, 2025
Study completion Nov 26, 2025
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- First posted
- Jun 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the pharmacokinetics (PK) of BPN14770 after a single oral administration of BPN14770 in participants with mild, moderate, and severe liver impairment compared with control participants with normal hepatic function.
Conditions
- Hepatic Impairment
Interventions
BPN14770Drug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Concentration Time Curve Extrapolated from Time 0 to Infinity (AUCinf) of BPN14770Time frame: Predose up to 240 hours postdose
- Maximum Observed Plasma Concentration (Cmax) of BPN14770Time frame: Predose up to 240 hours postdose
- Time Maximum Observed Plasma Concentration (Tmax) of BPN14770Time frame: Predose up to 240 hours postdose
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Division of Clinical Pharmacology, University of Miami
Miami, Florida
Orlando Clinical Research Center
Orlando, Florida
Texas Liver Institute
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.